Antiretroviral drug resistance surveillance among treatment-naive human immunodeficiency virus type 1-infected individuals in Angola: Evidence for low level of transmitted drug resistance

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 3156-3158

  Bártolo, Inês ^a   Rocha, Cheila ^a   Bartolomeu, José ^b   Gama, António ^c   Fonseca, Marlene ^d   Mendes, Ana ^d   Cristina, Filipa ^e   Thamm, Sven ^f   Epalanga, Marta ^b   Silva, Patrícia Cavaco ^a,g   Taveira, Nuno ^a,g  

^a UNIVERSITY OF LISBON   (Portugal)

^b Centro Nacional de Sangue   (Angola)

^c Medical Department   (Angola)

^d Hospital Militar Principal   (Angola)

^e Abbott Molecular Inc   (United States)

^f ABBOTT GMBH AND CO KG   (Germany)

^g INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE EGAS MONIZ   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; EFAVIRENZ; NEVIRAPINE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR;

ADULT; ANGOLA; ARTICLE; DRUG EFFICACY; FEMALE; GENETIC POLYMORPHISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STRAIN IDENTIFICATION; UNINDEXED SEQUENCE; VIRUS LOAD; VIRUS MUTATION; VIRUS TYPING;

EID: 67649910469     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00110-09     Document Type: Article

References (23)

1. Abegaz, W. E., Z. Grossman, D. Wolday, D. Ram, J. Kaplan, K. Sibide, T. Wuhib, S. Ismael, J. Nkengasong, T. Mekonen, H. Berhanu, T. Messele, S. Lulseged, S. Maayan, and Y. Mengistu. 2008. Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antivir. Ther. 13(Suppl. 2):89-94.
2. Bartolo, I., M. Epalanga, J. Bartolomeu, M. Fonseca, A. Mendes, A. Gama, and N. Taveira. 2005. High genetic diversity of human immunodeficiency virus type 1 in Angola. AIDS Res. Hum Retrovir. 21:306-310.
3. Bartolo, I., C. Rocha, J. Bartolomeu, A. Gama, R. Marcelino, M. Fonseca, A. Mendes, M. Epalanga, P. C. Silva, and N. Taveira. 2008. Highly divergent subtypes and new recombinant forms prevail in the HIV/AIDS epidemic in Angola: new insights into the origins of the AIDS pandemic. Infect. Genet. Evol. doi:10.1016/j.meegid.2008.05.003.
4. Baxter, J. D., J. M. Schapiro, C. A. Boucher, V. M. Kohlbrenner, D. B. Hall, J. R. Scherer, and D. L. Mayers. 2006. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J. Virol. 80:10794-10801.
5. Bennett, D. E., S. Bertagnolio, D. Sutherland, and C. F. Gilks. 2008. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir. Ther. 13(Suppl. 2):1-13.
6. Bennett, D. E., M. Myatt, S. Bertagnolio, D. Sutherland, and C. F. Gilks. 2008. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir. Ther. 13(Suppl. 2):25-36.
7. de Meyer, S., T. Vangeneugden, B. van Baelen, E. de Paepe, H. van Marck, G. Picchio, E. Lefebvre, and M. P. de Bethune. 2008. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res. Hum. Retrovir. 24:379-388.
8. Garrido, C., N. Zahonero, D. Fernandes, D. Serrano, A. R. Silva, N. Ferraria, F. Antunes, J. Gonzalez-Lahoz, V. Soriano, and C. de Mendoza. 2008. Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J. Antimicrob. Chemother. 61:694-698.
9. Geretti, A. M. 2007. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr. Opin. Infect. Dis. 20:22-32.
10. Gilks, C. F., S. Crowley, R. Ekpini, S. Gove, J. Perriens, Y. Souteyrand, D. Sutherland, M. Vitoria, T. Guerma, and K. De Cock. 2006. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368:505-510.
11. Gueudin, M., J. C. Plantier, V. Lemee, M. P. Schmitt, L. Chartier, T. Bourlet, A. Ruffault, F. Damond, M. Vray, and F. Simon. 2007. Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J. Acquir. Immune. Defic. Syndr. 44:500-505.
12. Kamoto, K., and J. Aberle-Grasse. 2008. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir. Ther. 13(Suppl. 2):83-87.
13. Lapadula, G., I. Izzo, F. Gargiulo, G. Paraninfo, F. Castelnuovo, E. Quiros-Roldan, G. Cologni, F. Ceresoli, N. Manca, G. Carosi, and C. Torti. 2008. Updated prevalence of genotypic resistance among HIV-1 positive patients naive to antiretroviral therapy: a single center analysis. J. Med. Virol. 80:747-753.
14. Nkengasong, J. N., C. Adje-Toure, and P. J. Weidle. 2004. HIV antiretroviral drug resistance in Africa. AIDS Rev. 6:4-12.
15. Pillay, V., J. Ledwaba, G. Hunt, M. Rakgotho, B. Singh, L. Makubalo, D. E. Bennett, A. Puren, and L. Morris. 2008. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir. Ther. 13(Suppl. 2):101-107.
16. Poveda, E., C. de Mendoza, L. Martin-Carbonero, A. Corral, V. Briz, J. Gonzalez-Lahoz, and V. Soriano. 2007. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J. Antimicrob. Chemother. 60:885-888.
17. Shafer, R. W., S. Y. Rhee, and D. E. Bennett. 2008. Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir. Ther. 13(Suppl. 2):59-68.
18. Shafer, R. W., S. Y. Rhee, D. Pillay, V. Miller, P. Sandstrom, J. M. Schapiro, D. R. Kuritzkes, and D. Bennett. 2007. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21:215-223.
19. Shet, A., L. Berry, H. Mohri, S. Mehandru, C. Chung, A. Kim, P. Jean-Pierre, C. Hogan, V. Simon, D. Boden, and M. Markowitz. 2006. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J. Acquir. Immune. Defic. Syndr. 41:439-446.
20. Somi, G. R., T. Kibuka, K. Diallo, T. Tuhuma, D. E. Bennett, C. Yang, C. Kagoma, E. F. Lyamuya, R. O. Swai, and S. Kassim. 2008. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antivir. Ther. 13(Suppl. 2):77-82.
21. UNAIDS. 2008, posting date. Epidemiological fact sheet on HIV and AIDS: core data on epidemiology and response. Angola. 2008 update. http://apps.who.int/globalatlas/predefinedReports/EFS2008/full/EFS2008-AO.pdf.
22. van de Vijver, D., A. Wensing, and C. Boucher. 2007. The epidemiology of transmission of drug resistant HIV-1, p. 17-36. In T. Leitner, B. Foley, B. Hahn, P. Marx, F. McCutchan, J. Mellors, S. Wolinsky, and B. Korber (ed.), HIV sequence compendium 2006/2007. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
23. World Health Organization. 2005, posting date. Angola: HIV/AIDS treatment. http://www.who.int/hiv/HIVCP-AGO.pdf.